Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ocular Therapeutix revenue
Ocular Therapeutix's revenue is $63.7 million.
What is Ocular Therapeutix's revenue?
- Ocular Therapeutix's revenue growth from 2014 to 2024 is 8,154.27%.
- Ocular Therapeutix has 228 employees, and the revenue per employee ratio is $279,486.
- Ocular Therapeutix's peak quarterly revenue was $17.1M in 2024(q4).
- Ocular Therapeutix peak revenue was $63.7M in 2024.
- Ocular Therapeutix annual revenue for 2023 was 58.4M, 13.49% growth from 2022.
- Ocular Therapeutix annual revenue for 2024 was 63.7M, 9.03% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Ocular Therapeutix historical revenue
Ocular Therapeutix's peak revenue was $63.7M in 2024. The peak quarterly revenue was $17.1M in 2024(q4).
Ocular Therapeutix's revenue increased from $772.0k in 2014 to $63.7M currently. That's a 8,154.27% change in annual revenue.
Ocular Therapeutix annual revenue
Ocular Therapeutix annual revenue over time
| Fiscal year / year | Ocular Therapeutix revenue |
|---|---|
| 2014 | $772,000 |
| 2015 | $1.8M |
| 2016 | $1.9M |
| 2017 | $1.9M |
| 2018 | $2.0M |
| 2019 | $4.2M |
| 2020 | $17.4M |
| 2021 | $43.5M |
| 2022 | $51.5M |
| 2023 | $58.4M |
| 2024 | $63.7M |
How accurately did Ocular Therapeutix's revenue projections match actual performance?
Ocular Therapeutix annual growth
Ocular Therapeutix saw the greatest revenue growth in 2020, when revenue increased by 311.71%.
Ocular Therapeutix had the lowest revenue growth in 2017, when revenue changed by 1.91%.
Ocular Therapeutix annual growth rate over time
| Year | Ocular Therapeutix growth |
|---|---|
| 2015 | 127%↑ |
| 2016 | 8%↑ |
| 2017 | 2%↑ |
| 2018 | 3%↑ |
| 2019 | 112%↑ |
| 2020 | 312%↑ |
| 2021 | 150%↑ |
| 2022 | 18%↑ |
| 2023 | 13%↑ |
| 2024 | 9%↑ |
Ocular Therapeutix quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Ocular Therapeutix quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | - | $97,000 | $143,000 | $505,000 |
| 2015 | $426,000 | $459,000 | $429,000 | $436,000 |
| 2016 | $458,000 | $441,000 | $477,000 | $511,000 |
| 2017 | $475,000 | $438,000 | $523,000 | $487,000 |
| 2018 | $340,000 | $648,000 | $498,000 | $504,000 |
| 2019 | $492,000 | $650,000 | $829,000 | $2.3M |
| 2020 | $2.6M | $1.6M | $5.9M | $7.3M |
| 2021 | $7.3M | $11.7M | $12.2M | $12.3M |
| 2022 | $13.2M | $12.3M | $12.0M | $14.1M |
| 2023 | $13.4M | $15.2M | $15.1M | $14.8M |
| 2024 | $14.8M | $16.4M | $15.4M | $17.1M |
Ocular Therapeutix jobs nearby
Do you work at Ocular Therapeutix?
Is Ocular Therapeutix transparent about its revenue structure?
Ocular Therapeutix financial information
| CEO | Antony Mattessich |
| Company Type | Public |
| Employees Number | 228 |
| Date Founded | 2006 |
| Headquarters | Bedford, Massachusetts |
| Number of Locations | 3 |
| Revenue | $63.7M |
| Net Income | -$71,038,000 |
| Gross Proft | $58.1M (2024) |
| PE Ratio | -0.85 |
| Market Capitalization | $164.5M |
| Total Assets | $149,289,000 |
| Ticker | OCUL |
Ocular Therapeutix jobs you might like
Ocular Therapeutix financing
Ocular Therapeutix received early financing of $995.8K on 2007-02-19.
| Series | Round size | Date |
|---|---|---|
| Series A | $996K | 02/2007 |
| Series B | $6M | 03/2008 |
| Series C | $15M | 06/2009 |
| Series C | $6M | 01/2011 |
| Series D | $14M | 02/2011 |
| Series D | $23.8M | 06/2013 |
| Post Ipo Equity | $88M | 06/2015 |
| Post Ipo Equity | $35.1M | 01/2018 |
| Post Ipo Debt | $37.5M | 03/2019 |
| Post Ipo Equity | $45M | 05/2020 |
Ocular Therapeutix investors
| Investors | Security type |
|---|---|
| Versant Ventures | Series B |
| SV Health Investors LLC | Series B |
| Polaris Partners | Series C |
| Versant Ventures | Series C |
| SV Health Investors LLC | Series C |
| Polaris Partners | Series C |
| Versant Ventures | Series C |
| SV Health Investors LLC | Series C |
| Ascension Ventures | Series D |
| Polaris Partners | Series D |
| Versant Ventures | Series D |
| SV Health Investors LLC | Series D |
| Ascension Ventures | Series D |
| Sparta Group | Series D |
| Versant Ventures | Series D |
| Baxter International Inc. | Series D |
| Polaris Venture Capital | Series D |
| Dan Burgess | Series D |
Search for jobs
Ocular Therapeutix highest paying jobs
Zippia gives an in-depth look into the details of Ocular Therapeutix, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ocular Therapeutix. The employee data is based on information from people who have self-reported their past or current employments at Ocular Therapeutix. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ocular Therapeutix. The data presented on this page does not represent the view of Ocular Therapeutix and its employees or that of Zippia.
Ocular Therapeutix may also be known as or be related to OCULAR THERAPEUTIX INC, OCULAR THERAPEUTIX, INC, Ocular Therapeutix, Ocular Therapeutix Inc and Ocular Therapeutix, Inc.